T1 mapping and survival in systemic light-chain amyloidosis

European Heart Journal

Volumn 36, Issue 4, 2015, Pages 244-251

  Banypersad, Sanjay M ^a,b,c   Fontana, Marianna ^a,b   Maestrini, Viviana ^a   Sado, Daniel M ^a   Captur, Gabriella ^a,b   Petrie, Aviva ^d   Piechnik, Stefan K ^e   Whelan, Carol J ^b   Herrey, Anna S ^a   Gillmore, Julian D ^b   Lachmann, Helen J ^b   Wechalekar, Ashutosh D ^b   Hawkins, Philip N ^b   Moon, James C ^a,c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Amyloid; Cardiomyopathy; CMR; ECV; Heart failure; T1 mapping

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID; BIOLOGICAL MARKER; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GADOTERATE MEGLUMINE; HYPERTENSIVE AGENT; LENALIDOMIDE; THALIDOMIDE; TROPONIN T; CONTRAST MEDIUM; GADOLINIUM; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; ANGIOCARDIOGRAPHY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIAC PATIENT; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DISEASE DURATION; EXTRACELLULAR SPACE; FEMALE; FOLLOW UP; HEART AMYLOIDOSIS; HEART DEATH; HEART EJECTION FRACTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL PREDICTION; SURVIVAL RATE; SYSTEMIC AMYLOID LIGHT CHAIN AMYLOIDOSIS; SYSTEMIC DISEASE; SYSTOLIC DYSFUNCTION; AMYLOIDOSIS; CARDIOMYOPATHY; HEART FAILURE; KAPLAN MEIER METHOD; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY;

AMYLOID; AMYLOIDOSIS; BIOMARKERS; CARDIOMYOPATHIES; CONTRAST MEDIA; FEMALE; GADOLINIUM; HEART FAILURE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84923392787     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu444     Document Type: Article

References (26)

1. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc 2012; 1: e000364.
2. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-Terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757.
3. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91: 141-157.
4. Perlini S, Salinaro F, Cappelli F, Perfetto F, Bergesio F, Alogna A, Mussinelli R, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G. Prognostic value of fragmented QRS in cardiac AL amyloidosis. Int J Cardiol 2013; 167: 2156-2161.
5. Miller F Jr, Bellavia D. Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study: reply. Eur Heart J Cardiovasc Imaging 2013; 14: 91-92.
6. Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010; 3: 333-342.
7. Bellavia D, Pellikka PA, Al-Zahrani GB, Abraham TP, Dispenzieri A, Miyazaki C, Lacy M, Scott CG, Oh JK, Miller Jr. F.A. Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocardiogr 2010; 23: 643-652.
8. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008; 10: 54.
9. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast t1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013; 6: 488-497.
10. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010; 122: 138-144.
11. Brooks J, Kramer CM, Salerno M. Markedly increased volumeof distribution of gadoliniumin cardiac amyloidosis demonstrated byTmapping. J Magn Reson Imaging 2013; 38: 1591-1595.
12. Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion byCMRin infiltrative heart disease. JACC Cardiovasc Imaging 2012; 5: 897-907.
13. Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, Cox AT, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Moon JC. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013; 6: 34-39.
14. Robbers LF, Baars EN, Brouwer WP, Beek AM, Hofman MB, Niessen HW, van Rossum AC, Marcu CB. T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions. Circ Cardiovasc Imaging 2012; 5: 423-426.
15. Bandula S, Banypersad SM, Sado D, Flett AS, Punwani S, Taylor SA, Hawkins PN, Moon JC. Measurement of tissue interstitial volume in healthy patients and those with amyloidosis with equilibrium contrast-enhanced MR imaging. Radiology 2013; 268: 858-864.
16. Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, Mulukutla SR, Simon MA, Shroff SG, Kuller LH, Schelbert EB. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 2014; 35: 657-664.
17. White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V, Flett AS, Piechnik SK, Robson MD, Hausenloy DJ, Sheikh AM, Hawkins PN, Moon JC. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging 2013; 6: 955-962.
18. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982; 49: 9-13.
19. Piechnik SK, Ferreira VM, DallArmellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD. Shortened modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson 2010; 12: 69.
20. Fontana M, White SK, Banypersad SM, Sado DM, Maestrini V, Flett AS, Piechnik SK, Neubauer S, Roberts N, Moon JC. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson 2012; 14: 88.
21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-381.
22. Heagerty PJ, Lumley T, Pepe MS. Time-dependentROCcurves for censored survival data and a diagnostic marker. Biometrics 2000; 56: 337-344.
23. Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G, Lachmann RH, Murphy E, Mehta A, Hughes DA, McKenna WJ, Taylor AM, Hausenloy DJ, Hawkins PN, Elliott PM, Moon JC. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 2012; 98: 1436-1441.
24. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, Sibley CT, Chen MY, Bandettini WP, Arai AE. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J 2012; 33: 1268-1278.
25. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989-995.
26. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007; 165: 710-718.